一分钟看懂
这是一项关于淋巴瘤的I 期 / II 期研究，登记的药物或干预包括Epcoritamab；Cyclophosphamide；Rituximab；Doxorubicin；Vincristine；Prednisone；Lenalidomide，当前状态为研究进行中，已停止招募。登记地点显示中国北京、福州、广州、郑州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Epcoritamab；Cyclophosphamide；Rituximab；Doxorubicin；Vincristine；Prednisone；Lenalidomide · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Fifth Medical Center of PLA General Hospital /ID# 230520 · 北京
- Peking University Third Hospital /ID# 228138 · 北京
- Fujian Medical University Union Hospital /ID# 231890 · 福州
- Sun Yat-Sen University Cancer Center /ID# 228033 · 广州
- Guangdong Provincial People's Hospital /ID# 228028 · 广州
- Nanfang Hospital of Southern Medical University /ID# 227916 · 广州
- Henan Cancer Hospital /ID# 228772 · 郑州
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 231221 · 武汉
- Hunan Cancer Hospital /ID# 231859 · 长沙
- The First Affiliated Hospital of Soochow University /ID# 228024 · 苏州
- The Affiliated Hospital of Xuzhou Medical College /ID# 228774 · 徐州
- The First Affiliated Hospital of Nanchang University /ID# 228771 · 南昌
- Jiangxi Provincial Cancer Hospital /ID# 231944 · 南昌
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 227724 · 上海
- West China Hospital, Sichuan University /ID# 231434 · 成都
- Tianjin Cancer Hospital /ID# 228135 · 天津
- The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 228154 · 杭州
- Zhejiang Cancer hospital /ID# 228776 · 杭州
公开的入选条件
- All Cohorts:
- * Life expectancy of \>= 3 months on standard of care (SOC).
- * Must have an Eastern Cooperative Oncology Group (ECOG) performance status score 0
- * Has one or more measurable disease sites:
- Fluorodeoxyglucose-positron emission tomography (FDGPET) scan demonstrating positive lesion compatible with computed tomography (CT) or magnetic resonance image (MRI)-defined anatomical tumor sites.
- \>= 1 measurable nodal lesion (long axis \> 1.5 cm and short axis \> 1.0 cm) or \>= 1.0 measurable extra-nodal lesion (long axis \>= 1 cm) on CT scan or MRI. Note: A previously irradiated lesion must have demonstrated progression or residual disease in the les
- Cohort 1 Part 1 (Monotherapy Safety Run-in) Specific Criteria:
- * Must have histologically confirmed CD20+ Diffuse large B-cell lymphoma (DLBCL), or High-grade B-cell lymphoma (HGCBL) with MYC and BCL2 and/or BCL6 translocations and DLBCL feature, and follicular Lymphoma (FL) at most recent (previous or current) representa
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05201248；登记信息更新于 2026-09-11。